When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
The American Society of Nuclear Cardiology visited Capitol Hill to advocate for a variety of issues. Cardiovascular Business spoke to the group's president to learn more.
Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.
Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.
The Center for Medicare and Medicaid Innovation (CMMI) has tested nearly 40 APMs, of which only two turned out to be successful, which does not bode well for meeting a 2030 deadline to transition to value-based payments.
Afnan Tariq, MD, discusses early data on a passive, device-agnostic AI platform for heart failure monitoring. “When clinicians are empowered with insights and able to act earlier, you're able to have a durable impact," he said.
While the Trump administration is pushing to accelerate clinical AI adoption, SCAI has emphasized that physicians must guide how the technology is implemented and governed.
The Medical Group Management Association explains some positive federal healthcare policy movement since the start of 2026, including extending telehealth and rural health payments, and possible solutions to the prior authorization burden in Medicare Advantage.
"It is almost a tidal wave of change from the federal level that is going to begin impacting state legislatures across the country. I think folks should probably be aware of that,” said RBMA's Kit Crancer.
